Enzolytics Company Description

Enzolytics Inc., a drug development company, focuses to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases.

Its patented anti-HIV therapeutics and a proprietary methodology for producing human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy.

The company has clinically tested anti-HIV therapeutics. In addition, the company’s proprietary cell line produces human monoclonal antibodies that target and neutralizes the HIV virus.

Enzolytics Inc. is based in Plano, Texas.

Enzolytics, Inc.

Country	United States
Industry	Biotechnology
Sector	Healthcare
Employees	1
CEO	Steven Sharabura

Contact Details

Address: 2000 North Central Expressway Plano, Delaware 75074 United States
Phone	972 292 9414
Website	enzolytics.com

Stock Details

Ticker Symbol	ENZC
Exchange	OTCMKTS
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
ISIN Number	US2941121079
SIC Code	2836

Key Executives

Name	Position
Steven Sharabura	Chief Executive Officer
Harry H. Zhabilov Jr., BSc, McS Science	CSO and Chairman
Charles S. Cotropia	President and Director
Diana Zhabilov	Chief Financial Officer